FDA Alerts on Risperdal

FDA Alert on Risperdal

In 2004, the Food and Drug Administration (FDA) warned Janssen Pharmaceutica that their advertising and promotional practices for Risperdal were misleading. The FDA was particularly concerned that the pharmaceutical company did not adequately address the increased risk of hyperglycemia and diabetes in patients taking the drug.

As a result of the FDA’s actions, it is now required that all manufacturers of atypical antipsychotic medications warn the public of these conditions. This FDA alert was prompted by Janssen’s 2003 letter to physicians that glossed over some of the health risks associated with Risperdal use.

  • - -
  • By clicking the "Submit" button below, you agree that law firms you are matched with may contact you by telephone even if you are on a federal or state Do Not Call registry. Up to 10 law firms may respond to your request within approximately 2 weeks. In some cases 3 or more firms may respond to your request after 30 days. Use of this site is subject to our Terms of Use.

Home | Sitemap

Website Design & Web Positioning by Wise Law Group

Copyright ©2012- All rights reserved | Terms of Use

This page contains information on the FDA Alert on Risperdal.